|Study Type:||Phase I|
|Stage:||Follow up complete|
|Study Start Date:||NA|
|Study Made Public:||NA|
A Phase I clinical trial to evaluate the safety and immunogenicity of Polyvalent env (A, B, C, E)/gag (C) DNA and gp 120 (A,B,C,E) Protein/GLA-SE HIV-1 Vaccines (PDPHV-201401) as either a prime-boost regimen or co-administered in repeated doses, in healthy, HIV-1 uninfected adult participants
HVTN 124 is a Phase I clinical trial to evaluate the safety and immunogenicity of env (A,B,C,A/E)/gag (C) DNA and gp120 (A,B,C,A/E) protein/GLA-SE HIV-1 vaccines (PDPHV-201401).
Sign in to see full information about this study and to download study data.
ProductsProduct info coming soon!
No integrated data is available for this study.
No non-integrated data is available for this study.